The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.
Beam Therapeutics, a US-based genomic therapy developer spun out of Harvard University, closed its initial public offering at $207m yesterday.
The company priced 10.6 million shares at the top of a $15 to $17 range to raise $180m last week having already increased the number of shares it was offering. The shares closed at $24.99 yesterday and the IPO’s underwriters acquired a further 1.59 million shares to close the offering.
Beam is utilising genomic base-editing technology to…
